Analyst Ratings for Exact Sciences
Portfolio Pulse from Benzinga Insights
In the last quarter, Exact Sciences (NASDAQ:EXAS) received 10 bullish, 1 somewhat bullish, and 2 indifferent analyst ratings. The company's average 12-month price target is $93.85, up 15.24% from the previous average of $81.44.
June 23, 2023 | 9:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Exact Sciences received mostly bullish analyst ratings in the last quarter, with an average 12-month price target of $93.85, up 15.24% from the previous average.
The majority of analyst ratings for Exact Sciences are bullish, indicating a positive outlook for the stock. The increase in the average 12-month price target by 15.24% also suggests that analysts expect the stock to perform well in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100